Results 91 to 100 of about 338,185 (301)

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment [PDF]

Frontiers in Immunology, 2021
The magnitude of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has prompted the repurposing of several drugs to quickly stop the morbidity, mortality, and spread of this new disease.
openaire   +4 more sources

Development of a Personalized Visualization and Analysis Tool to Improve Clinical Care in Complex Multisystem Diseases With Application to Scleroderma

Arthritis Care &Research, EarlyView.
Objective In complex diseases, it is challenging to assess a patient's disease state, trajectory, treatment exposures, and risk of multiple outcomes simultaneously, efficiently, and at the point of care. Methods We developed an interactive patient‐level data visualization and analysis tool (VAT) that automates illustration of the trajectory of a ...
Ji Soo Kim, John Scott, Lauren Fisher, Lauren N. Smith, Willie Stewart, Adrianne Woods, Rob Smithwright, Diane Koher, Parastoo Aslanbeik, Aalok B. Shah, Brad Tibbils, Samantha I. Pitts, Ayse P. Gurses, Yushi Yang, Ana‐Maria Orbai, Antony Rosen, Laura K. Hummers, Scott L. Zeger, Ami A. Shah   +18 more
wiley   +1 more source

Review of COVID-19 treatment

Journal of Research in Pharmacy Practice, 2020
Many contagious diseases, such as plague or cholera, played a role in changing the pathway of history. In this respect, although coronavirus was not as dangerous as novel diseases such as swine flu and Ebola, the spread and the power of coronavirus ...
Somayeh Sadeghi, Mahnaz Momenzadeh, Peiman Nasri, Mina Nickpour   +3 more
doaj   +1 more source

Update on Remdesivir in the Treatment of Novel Coronavirus Pneumonia

Progress in Microbes and Molecular Biology, 2023
Worldwide epidemic prevention and control remain under significant stress due to the global novel coronavirus disease 2019 (COVID-19) pandemic and the ongoing emergence of variants like Omicron.
Huang Feng, K. Vijaya Lakshmi, Chin Tat Ng, Murthy Sasikumar, Masita Arip, Masriana Hassan, Voon Kin Chin, Mogana Rajagopal, Omotayo Fatokun, N. Parvathi, Malarvili Selvaraja   +10 more
doaj   +1 more source

Potential treatments of COVID-19: Drug repurposing and therapeutic interventions

Journal of Pharmacological Sciences, 2023
The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The infection is caused when Spike-protein (S-protein) present on the surface of SARS-CoV-2 interacts with human cell surface receptor, Angiotensin-converting enzyme 2 (ACE2). This binding facilitates SARS-CoV-2 genome entry into the human
Pawan Kumar Raghav, Zoya Mann, Simran Kaur Ahluwalia, Raja Rajalingam   +3 more
openaire   +5 more sources

Physician Referral Patterns to Physical Therapists for Managing Knee Osteoarthritis: A Retrospective Analysis of Electronic Health Records From an Integrated Health System

Arthritis Care &Research, EarlyView.
Objective This study aims to describe the frequency and timing of physician referrals to physical therapists (PTs) and other treatments prescribed over 12 months in patients with recent onset of knee osteoarthritis (KOA). The study also aims to identify determinants of early PT referrals.
Samannaaz S. Khoja, Joel M. Stevans, Gustavo J. Almeida, Clair Smith, Janet K. Freburger   +4 more
wiley   +1 more source

Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19 [PDF]

Терапевтический архив
Aim. To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults. Materials and methods. The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non ...
Alebai U. Sabitov, Dmitry A. Lioznov, Konstantin V. Zhdanov, Elena P. Tikhonova, Elena V. Esaulenko, Olga P. Kovtun, Pavel L. Kuznetsov, Pavel V. Sorokin   +7 more
doaj   +1 more source

Experience in Using Antiviral Agents for the Treatment of Novel Coronavirus Infection (COVID-19) in Kyrgyzstan

Безопасность и риск фармакотерапии, 2021
The national clinical guidelines for the treatment of novel coronavirus infection (COVID-19) are the main source of information and the reference point for clinical decision-making by healthcare professionals in the Kyrgyz Republic.
A. A. Zurdinova, A. Z. Kutmanova
doaj   +1 more source

Antiviral Drug Discovery for the Treatment of COVID-19 Infections

Viruses, 2022
The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus. COVID-19 vaccines have proven to be successful in protecting the vaccinated from infection, reducing the severity of disease, and deterring the transmission of infection. However, COVID-19
Teresa I. Ng, Ivan Correia, Jane Seagal, David A. DeGoey, Michael R. Schrimpf, David J. Hardee, Elizabeth L. Noey, Warren M. Kati   +7 more
openaire   +3 more sources

Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis

Arthritis Care &Research, EarlyView.
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan, Catherine M. Guly, Gabriele Simonini, Stuart Y. Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier   +7 more
wiley   +1 more source